Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer

[摘要] In January 2010, a panel of Canadian oncologists with particular expertise in colorectal cancer (CRC) gathered to develop a consensus guideline on the use of therapies against the epidermal growth factor receptor (EGFR) in the management of metastatic CRC (mCRC). This paper uses a case-based approach to summarize the consensus recommendations developed during that meeting.These are the consensus recommendations: Testing for theKRASstatus of the tumour should be performed as soon as an EGFR inhibitor is being considered as an option for treatment.Anti-EGFR therapies are not recommended for the treatment of patients with tumours showing mutatedKRASstatus.For a patient with wild-typeKRASand an Eastern Cooperative Oncology Group status of 0-2, whose mCRC has previously been treated with a fluoropyrimidine, irinotecan, and oxaliplatin, switching to an EGFR inhibitor is a recommended strategy.Cetuximab, cetuximab plus irinotecan, and panitumumab are all options for third-line therapy in patients with wild-typeKRAS , provided that tolerability is acceptable.

[学科分类] 肿瘤学